Kato Kambartel

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Anna Kron, Christina Alidousty, Matthias Scheffler et al. · Annals of Oncology · 2018 · 211 citations · Full text

Medicine, Molecular Genetics, Oncology +17

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

Felix Dietlein, Bastian Kalb, Mladen Jokić et al. · Cell · 2015 · 127 citations

Medicine, Medicinal Chemistry, Oncology +14

Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy

Anna Kron, Matthias Scheffler, Carina Heydt et al. · Journal of Thoracic Oncology · 2020 · 69 citations · Full text

Medicine, Genetics, Oncology +14

Targeting <i>FGFR1</i>-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.

Lucia Nogová, Lecia V. Sequist, Philippe A. Cassier et al. · Journal of Clinical Oncology · 2014 · 42 citations

Medicine, Oncology, Pharmacology +14

Lazarus-Type Tumour Response to Therapy with Nivolumab for Sarcomatoid Carcinomas of the Lung

Christian Roesel, Kato Kambartel, Uldis Kopeika et al. · Current Oncology · 2019 · 23 citations · Full text

Life Sciences, Immunology, Oncology +17